Systemic Lupus Erythematosus (SLE) Clinical Trials

47 recruiting

Systemic Lupus Erythematosus (SLE) Trials at a Glance

47 actively recruiting trials for systemic lupus erythematosus (sle) are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 1 with 26 trials, with the heaviest enrollment activity in Beijing, Wuhan, and Hangzhou. Lead sponsors running systemic lupus erythematosus (sle) studies include China Immunotech (Beijing) Biotechnology Co., Ltd., Beijing GoBroad Hospital, and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Browse systemic lupus erythematosus (sle) trials by phase

Treatments under study

About Systemic Lupus Erythematosus (SLE) Clinical Trials

Looking for clinical trials for Systemic Lupus Erythematosus (SLE)? There are currently 47 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Lupus Erythematosus (SLE) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Lupus Erythematosus (SLE) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 47 trials

Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled54 locationsNCT07175285
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled3 locationsNCT07332481
Recruiting

Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus

Systemic Lupus Erythematosus (SLE)
Shanghai Jiao Tong University School of Medicine60 enrolled1 locationNCT07425730
Recruiting

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

Systemic Lupus Erythematosus (SLE)
AstraZeneca200 enrolled6 locationsNCT06314282
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting

Lupus Landmark Study: A Prospective Registry and Biorepository

Systemic Lupus Erythematosus (SLE)Lupus NephritisNeuropsychiatric Systemic Lupus Erythematosus
Lupus Research Alliance3,500 enrolled25 locationsNCT05934149
Recruiting
Phase 2

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.120 enrolled1 locationNCT07447986
Recruiting
Early Phase 1

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School15 enrolled1 locationNCT06946485
Recruiting
Phase 4

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Bristol-Myers Squibb35 enrolled4 locationsNCT06875960
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Systemic Lupus Erythematosus (SLE)Rheumatic DiseasesPediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT07490041
Recruiting
Phase 1

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)
Sanofi62 enrolled8 locationsNCT06647069
Recruiting
Phase 2

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Nanjing University School of Medicine50 enrolled1 locationNCT07340463
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital18 enrolled1 locationNCT06585514
Recruiting
Phase 1

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)
Beijing GoBroad Hospital27 enrolled1 locationNCT06822881
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting
Phase 1

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd.18 enrolled3 locationsNCT07444307
Recruiting
Phase 1Phase 2

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

SLESystemic Lupus Erythematosus (SLE)
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976